Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ±FG-3019 as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC).

被引：2
|
作者：
Picozzi, Vincent J.
Rocha, Flavio G.
Helton, Scott
Mody, Kabir
Asbun, Horacio
Pishvaian, Michael J.
Jackson, Patrick G.
Etheridge, Tina
Carney, Mairead
Neff, Thomas B.
Porter, Seth
Crans, Gerald
Valone, Frank
Shi, Wen
机构：
[1] Virginia Mason Med Ctr, Seattle, WA 98101 USA
[2] Mayo Clin, Jacksonville, FL 32224 USA
[3] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA
[4] FibroGen Inc, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.457
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
457
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A multi-center, open-label, randomized controlled trial of nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine for first-line treatment of advanced pancreatic cancer (PC)
    Jin, M.
    Liu, H.
    Lin, Z.
    Xue, J.
    Liu, J.
    Bao, L.
    Luo, Z.
    Yu, X.
    Li, S.
    Hu, J.
    Zhang, T.
    ANNALS OF ONCOLOGY, 2022, 33 : S311 - S311
  • [32] Phase II LAPACT Trial of Nab-Paclitaxel Plus Gemcitabine for Patients With Locally Advanced Pancreatic Cancer
    Bekaii-Saab, Tanios
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (03) : 9 - 10
  • [33] APACT: Phase III, Multicenter, International, Open-Label, Randomized Trial of Adjuvant nab-Paclitaxel Plus Gemcitabine (nab-P/G) Versus Gemcitabine (G) for Surgically Resected Pancreatic Adenocarcinoma
    Ko, A.
    Reni, M.
    Riess, H.
    Pelzer, U.
    O'Reilly, E. M.
    Winter, J.
    Oh, D. Y.
    Li, C. P.
    Tortora, G.
    Chang, H. M.
    Lopez, C. D.
    Tabernero, J.
    Van Cutsem, E.
    Philip, P.
    Goldstein, D.
    Berlin, J. D.
    Ferrara, S.
    Li, M.
    Lu, B.
    Romano, A.
    Marks, H.
    Biankin, A.
    Tempero, M. A.
    PANCREAS, 2019, 48 (10) : 1464 - 1464
  • [34] A phase 1 study of neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel, followed by concurrent chemoradiation with gemcitabine, sorafenib, and vorinostat in locally advanced pancreatic cancer
    Park, Haeseong
    Poklepovic, Andrew
    CANCER RESEARCH, 2014, 74 (19)
  • [35] nab-Paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC): Interim efficacy and safety results from the Phase 2 LAPACT Trial
    Philip, P. A.
    Lacy, J.
    Portales, F.
    Sobrero, A.
    Pazo-Cid, R.
    Manzano Mozo, J. L.
    Kim, E. S.
    Dowden, S.
    Zakari, A.
    Borg, C.
    Terrebonne, E.
    Rivera Herrero, F.
    Shiansong Li, J.
    Ong, T. J.
    Nydam, T.
    Hammel, P.
    ANNALS OF ONCOLOGY, 2017, 28
  • [36] HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P plus GEM) for unresectable locally advanced pancreatic cancer (LAPC)
    Tanimoto, A.
    Yagisawa, M.
    Nakano, S.
    Kawamoto, Y.
    Yuki, S.
    Ishiguro, A.
    Takahata, T.
    Sato, A.
    Iwanaga, I.
    Ehira, N.
    Uebayashi, M.
    Muto, O.
    Sasaki, T.
    Hatanaka, K.
    Tateyama, M.
    Wakabayashi, T.
    Dazai, M.
    Minami, S.
    Sakata, Y.
    Komatsu, Y.
    ANNALS OF ONCOLOGY, 2019, 30
  • [37] Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer.
    Yamada, Suguru
    Fujii, Tsutomu
    Takano, Nao
    Takami, Hideki
    Suenaga, Masaya
    Niwa, Yukiko
    Hayashi, Masamichi
    Iwata, Naoki
    Kanda, Mitsuro
    Kobayashi, Daisuke
    Tanaka, Chie
    Nakayama, Goro
    Sugimoto, Hiroyuki
    Koike, Masahiko
    Fujiwara, Michitaka
    Kodera, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [38] A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer
    Bodeker, Kellie L.
    Smith, Brian J.
    Berg, Daniel J.
    Chandrasekharan, Chandrikha
    Sharif, Saima
    Fei, Naomi
    Vollstedt, Sandy
    Brown, Heather
    Chandler, Meghan
    Lorack, Amanda
    McMichael, Stacy
    Wulfekuhle, Jared
    Wagner, Brett A.
    Buettner, Garry R.
    Allen, Bryan G.
    Caster, Joseph M.
    Dion, Barbara
    Kamgar, Mandana
    Buatti, John M.
    Cullen, Joseph M.
    REDOX BIOLOGY, 2024, 77
  • [39] PanCO: An open-label, single-arm pilot study of Oncosil™ in patients with unresectable locally advanced pancreatic adenocarcinoma in combination with FOLFIRINOX or gemcitabine plus nab-paclitaxel chemotherapies
    Harris, M.
    Croagh, D.
    Aghmesheh, M.
    Nagrial, A.
    Nguyen, N.
    Wasan, H.
    Ajithkumar, T.
    Kraszewski, A.
    Maher, T.
    Ross, P.
    ANNALS OF ONCOLOGY, 2018, 29 : 39 - 39
  • [40] PANCO: AN OPEN-LABEL, SINGLE-ARM PILOT STUDY OF PHOSPHORUS-32 (ONCOSILT) MICROPARTICLES IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA (LAPC) IN COMBINATION WITH FOLFIRINOX OR GEMCITABINE plus NAB-PACLITAXEL (GNP) CHEMOTHERAPIES
    Ross, Paul J.
    Croagh, Daniel
    Aghmesheh, Morteza
    Nagrial, Adnan
    Kwan, Vu
    Nguyen, Nam Q.
    Nikfarjam, Mehrdad
    Wasan, Harpreet
    Ajithkumar, Thankamma
    Iwuji, Chinenye
    Hendlisz, Alain
    Warrener, Michael
    Kenny, Daniel
    Harris, Marion
    GASTROENTEROLOGY, 2020, 158 (06) : S523 - S524
12345